fashion -WSS

fashion

author：hotspot 2025-09-02 05:44:03 - browse：76

NICOLAS MAETERLINCK/BELGA MAG/AFP via Getty Images

LONDON — Novavax, the beleaguered maker of a Covid-19 vaccine, just got a boost of its own.

The French pharma company Sanofi on Friday said it had reached a licensing deal to sell Novavax’s Covid shot going forward as well as to try to combine the vaccine with Sanofi’s own flu shot. The pact includes a $500 million upfront payment, with up to $700 million more on the table if certain regulatory and launch milestones are reached.

While Novavax’s stock soared during the pandemic as the vaccine race was underway, the company failed to get its shot authorized in the U.S. market until July 2022, long after the makers of mRNA vaccines had reaped billions in sales. Sales have sputtered along since then, and last year, the Maryland-based company warned that that it may not be able to stay in business.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： The high cost of giving birth even with insurance
Next article： South Korea throws huge K

leisure time

WSS

Hawaii wildfires fueled by Hurricane Dora's winds prompt evacuations

Telehealth for opioid use disorder is lifesaving

Walmart eyes Medicare Advantage provider ChenMed

Wayne Brady comes out as pansexual: 'Free to love whomever I want'

How to use technology to prevent future drug shortages

South Korea throws huge K

Wikipedia

fashion

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

focus

At least 13 dead in Texas as scorching temps continue

FDA panel endorses Alnylam’s heart drug — after picking it apart

Medical leaders decry Supreme Court decision on affirmative action

FDA panel endorses Alnylam’s heart drug — after picking it apart

The high cost of giving birth even with insurance

Will the IRA bring competition to the biologics market?

Medical records are filled with copy

Twitch streamer Kai Cenat speaks out for 1st time since causing mayhem with Union Square giveaway

Dobbs anniversary: the lost opportunity of abortion as health care

A biotech analyst on neuroscience, placebo effect, not over

entertainment

Hawaii wildfires fueled by Hurricane Dora's winds prompt evacuations

South Korea throws huge K

Friends ask where James Watson's attitudes about race came from

Friends ask where James Watson's attitudes about race came from

Long Covid needs a new name — and a new frame

For Cytokinetics, FDA rejection of heart drug would help, not hinder

hotspot

leisure time

explore

focus